Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study design
Future Oncology · 2024
DOI: 10.2217/fon-2023-0774 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Oncology, 2024. Verfasst von Robert L Ferris und 9 weiteren Autor:innen. Beteiligte Einrichtung: University of Pittsburgh Medical Center, Pittsburgh, PA 15232, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma, Squamous Cell, Head and Neck Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Merck KGaA.
Abstract (Originalsprache)
There is a significant unmet need and lack of treatment options for patients with resected, high-risk, cisplatin-ineligible locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). Xevinapant, a first-in-class, potent, oral, small-molecule IAP inhibitor, is thought to restore cancer cell sensitivity to chemotherapy and radiotherapy in clinical and preclinical studies. We describe the design of XRay Vision (NCT05386550), an international, randomized, double-blind, phase III study. Approximately 700 patients with resected, high-risk, cisplatin-ineligible LA SCCHN will be randomized 1:1 to receive 6 cycles of xevinapant or placebo, in combination with radiotherapy for the first 3 cycles. The primary end point is disease-free survival, and secondary end points include overall survival, health-related quality of life, and safety. Squamous cell carcinoma is the most common form of head and neck cancer (SCCHN) and includes cancers of the lips, mouth, throat, tongue and voice box. It is called ‘locally advanced' when the cancer has spread to nearby areas but not to other parts of the body. Few treatment options are available for people with locally advanced SCCHN who have had surgery and are unable to receive a type of chemotherapy called cisplatin. Xevinapant is being developed as a possible new type of cancer treatment. It is a liquid that is taken by mouth or given through a feeding tube. Adding xevinapant to the standard treatment – called radiotherapy – aims to make radiotherapy more effective against the cancer. Researchers have started a large, international, phase III study called XRay Vision to see if adding xevinapant to radiotherapy can help stop the cancer from coming back after surgery and help people live longer. Clinical Trial Registration: NCT05386550 (ClinicalTrials.gov).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Pittsburgh Medical Center, Pittsburgh, PA 15232, USA.
- University of Birmingham, Birmingham, B15 2TT, UK.
- Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- National Cancer Center Hospital East, Kashiwa, Japan.
- University of California San Francisco, San Francisco, CA 94143, USA.
- Merck Healthcare KGaA, Darmstadt, Germany.
ORCID-Profile: Robert L Ferris, Hisham Mehanna, Jonathan D Schoenfeld, Makoto Tahara, Sue S Yom, Robert Haddad, André König, Christophe Le Tourneau
Förderung
- Merck KGaA
Zitieren
APA
Ferris, R. L., Mehanna, H., Schoenfeld, J. D., Tahara, M., Yom, S. S., Haddad, R., König, A., Witzler, P., Bajars, M., & Tourneau, C. L. (2024). Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study design. Future Oncology. https://doi.org/10.2217/fon-2023-0774
Vancouver
Ferris RL, Mehanna H, Schoenfeld JD, Tahara M, Yom SS, Haddad R, et al. Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study design. Future Oncology. 2024. doi:10.2217/fon-2023-0774
BibTeX
@article{Ferris2024,
author = {Ferris, Robert L and Mehanna, Hisham and Schoenfeld, Jonathan D and Tahara, Makoto and Yom, Sue S and Haddad, Robert and König, André and Witzler, Pauline and Bajars, Marcis and Tourneau, Christophe Le},
title = {Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study design},
journal = {Future Oncology},
year = {2024},
doi = {10.2217/fon-2023-0774}
}
EUVIMED